Dillard's Inc. DDS posted third-quarter fiscal 2024 results, wherein the top and bottom lines surpassed the Zacks Consensus ...

Ardelyx’s Xphozah sales rise, but CMS ruling creates uncertainty. See why ARDX stock faces risks amid rising competition and ...

The company's high SG&A expenses and lack of growth make it difficult to compete against lower-priced alternatives, ...

Our non-GAAP R&D and SG&A expense is now expected to be between $115 million and $125 million for the full year ending December 31, ...

Currently, companies typically include in their income statements expense captions for selling, general and administrative expenses, cost of ...

Selling, General and Administrative (SG&A) Expenses: SG&A expenses decreased to $2.74 million in the third quarter of 2024 ...

Despite revenue decline, Fortrea Holdings Inc (FTRE) showcases strong demand with a solid book-to-bill ratio and promising growth prospects.